These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32451349)

  • 1. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.
    Rijensky NM; Blondheim Shraga NR; Barnea E; Peled N; Rosenbaum E; Popovtzer A; Stemmer SM; Livoff A; Shlapobersky M; Moskovits N; Perry D; Rubin E; Haviv I; Admon A
    Mol Cell Proteomics; 2020 Aug; 19(8):1360-1374. PubMed ID: 32451349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
    Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
    Mol Cell Proteomics; 2018 Nov; 17(11):2132-2145. PubMed ID: 30072578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
    Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
    Mol Cell Proteomics; 2019 Jun; 18(6):1255-1268. PubMed ID: 31154438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
    Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.
    Shraibman B; Kadosh DM; Barnea E; Admon A
    Mol Cell Proteomics; 2016 Sep; 15(9):3058-70. PubMed ID: 27412690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nature and extent of contributions by defective ribosome products to the HLA peptidome.
    Bourdetsky D; Schmelzer CE; Admon A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1591-9. PubMed ID: 24715725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.
    Clement CC; Becerra A; Yin L; Zolla V; Huang L; Merlin S; Follenzi A; Shaffer SA; Stern LJ; Santambrogio L
    J Biol Chem; 2016 Mar; 291(11):5576-5595. PubMed ID: 26740625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
    Backert L; Kowalewski DJ; Walz S; Schuster H; Berlin C; Neidert MC; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Kanz L; Salih HR; Kohlbacher O; Weisel K; Rammensee HG; Stevanovic S; Walz JS
    Oncotarget; 2017 Jul; 8(27):43915-43924. PubMed ID: 28159928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble plasma HLA peptidome as a potential source for cancer biomarkers.
    Bassani-Sternberg M; Barnea E; Beer I; Avivi I; Katz T; Admon A
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18769-76. PubMed ID: 20974924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
    Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
    J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery.
    Ritz D; Gloger A; Neri D; Fugmann T
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27862975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.
    Nanaware PP; Jurewicz MM; Leszyk JD; Shaffer SA; Stern LJ
    Mol Cell Proteomics; 2019 Mar; 18(3):490-503. PubMed ID: 30573663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides presented by HLA class I molecules in the human thymus.
    Espinosa G; Collado JA; Scholz E; Mestre-Ferrer A; Kuse N; Takiguchi M; Carrascal M; Canals F; Pujol-Borrell R; Jaraquemada D; Alvarez I
    J Proteomics; 2013 Dec; 94():23-36. PubMed ID: 24029068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
    Jarmalavicius S; Welte Y; Walden P
    J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.